Discover

BDX
Becton, Dickinson and Company
154.51
400 x 154.84
200 x 156.89
bid
ask
-
1.83
1.17%
300 @ 04:00 PM
156.87 +2.36 (1.53%)
Ytd 1.27%
1y -13.20%
153.25
day range
157.56
129.83
52 week range
185.39
Open 154.56 Prev Close 156.34 Low 153.25 High 157.56 Mkt Cap 55.98B
Vol 1.82M Avg Vol 2.79M EPS 6.12 P/E 25.25 Forward P/E 11.44
Beta 0.31 Short Ratio 4.18 Inst. Own 96.29% Dividend 4.20 Div Yield 2.69
Ex Div Date 03-10 Earning 05-07 50-d Avg 165.87 200-d Avg 152.51 1yr Est 196.08
Earning
Date For Estimate Reported Surprise surprise %
2026-05-07 2026-03 2.77 N/A N/A N/A
2026-02-09 2025-12 2.82 2.91 0.09 3.19%
2025-11-06 2025-09 3.92 3.96 0.04 1.02%
2025-08-07 2025-06 3.42 3.68 0.26 7.60%
2025-05-01 2025-03 3.28 3.35 0.07 2.13%
2025-02-05 2024-12 2.98 3.43 0.45 15.10%
Upgrade / Downgrade
Date Firm Action From To
2026-03-23 Argus Research Upgrade Buy Buy
2026-02-11 Citigroup Upgrade Buy Buy
2026-02-10 JP Morgan Upgrade Neutral Neutral
2026-02-10 Jefferies Upgrade Buy Buy
2026-02-10 RBC Capital Upgrade Sector Perform Sector Perform
2026-02-10 Citigroup Upgrade Buy Buy
Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Insider Holder
Date Name Relation Quantity Description
2025-11-25 DELOREFICE CHRISTOPHER Chief Financial Officer 22.98K Stock Award(Grant)
2026-03-25 FELD MICHAEL Officer 21.23K Sale
2025-09-09 FRASER CLAIRE Director 22.23K Sale
2025-11-25 GOETTE ROLAND Officer 18.78K Stock Award(Grant)
2026-01-26 JONES CHRISTOPHER IAN MONTAGUE Director 24.30K Stock Award(Grant)
2025-11-25 MUHSIN BILAL Officer 21.75K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Vanguard Group Inc 36.68M 5.67B 12.88%
2025-12-30 Blackrock Inc. 27.65M 4.27B 9.71%
2025-12-30 T. Rowe Price Investment Management, Inc. 14.38M 2.22B 5.05%
2025-12-30 State Street Corporation 13.99M 2.16B 4.91%
2025-12-30 First Eagle Investment Management, LLC 11.65M 1.80B 4.09%
2025-12-30 Massachusetts Financial Services Co. 9.49M 1.47B 3.33%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App 8.96M 1.38B 3.15%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 8.97M 1.39B 3.15%
2026-01-30 First Eagle Funds-First Eagle Global Fund 8.06M 1.25B 2.83%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 7.23M 1.12B 2.54%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund 6.21M 959.82M 2.18%
2026-01-30 iShares Trust-iShares Core S&P 500 ETF 3.69M 569.90M 1.30%
Dividend
Dividend Date
1.05 2026-03-10
1.05 2025-12-08
1.04 2025-09-08
1.04 2025-06-09
1.04 2025-03-10
1.04 2024-12-09
Split
Split Date
1025 : 1000 2022-04-01
2 : 1 1998-08-21
2 : 1 1996-08-16
2 : 1 1993-03-01
2 : 1 1986-03-03